Retatrutide has emerged as a new pharmaceutical in the fight against obesity. This novel drug, classified as a dual GLP-1 and GIP receptor agonist, shows promising results in clinical trials. By stimulating these receptors, Retatrutide suppresses appetite, {promotesglucose regulation, and ultimately leads to significant slimming. While further inv